<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-ONC-12002908</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2012-12-27</date_registration>
      <primary_sponsor>Peking University People's Hospital</primary_sponsor>
      <public_title>The sencond allogeneic hematopoietic stem cell transplant for the treatment of leukemia relapse after donor lymphocyte infusion</public_title>
      <acronym />
      <scientific_title>The sencond allogeneic hematopoietic stem cell transplant for the treatment of leukemia relapse after donor lymphocyte infusion</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2013-01-01</date_enrolment>
      <type_enrolment />
      <target_size>1:30;</target_size>
      <recruitment_status>Completed</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=6646</url>
      <study_type>Observational study</study_type>
      <study_design>Case-Control study</study_design>
      <phase>Other</phase>
      <hc_freetext>leukemia</hc_freetext>
      <i_freetext>1:second allo-HSCT  ;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Yu Wang</firstname>
        <middlename />
        <lastname />
        <address>11 Xizhimen Street South, Beijing</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 10 88324952</telephone>
        <email>ywyw3172@sina.com</email>
        <affiliation>Peking University People's Hospital</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Xiao-Jun Huang</firstname>
        <middlename />
        <lastname />
        <address>11 Xizhimen Street South, Beijing</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 10 88326006</telephone>
        <email>huangxiaojun@bjmu.edu.cn</email>
        <affiliation />
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>1. refractoty/relapsed leukemia patients undergoing first allo-HSCT relapsed after prophylactic DLI;
2. leukemia patients undergoing first allo-HSCT in CR relapsed after DLI for positive MRD.</inclusion_criteria>
      <agemin>2</agemin>
      <agemax>60</agemax>
      <gender>Both</gender>
      <exclusion_criteria>1. uncontrolled severe infection;
2. organ failure;
3. death within 30 days after relapse following first allo-HSCT.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>disease free survival rate;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Peking University People's Hospital</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2012-12-21</approval_date>
        <contact_name />
        <contact_address />
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>